Evaluation of MEDI8852, an anti-influenza A monoclonal antibody, in treating acute uncomplicated influenza

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 11, 2018, Pages

  Omar Ali, S ^a   Takas, Therese ^a   Nyborg, Andrew ^a   Shoemaker, Kathryn ^a   Kallewaard, Nicole L ^a   Chiong, Rafael ^b   Dubovsky, Filip ^a   Mallory, Raburn M ^a  

^a MEDIMMUNE   (United States)

^b Kendall South Medical Center   (United States)

Author keywords

Influenza; Monoclonal antibody; Safety; Treatment

Indexed keywords

ANTIVIRUS AGENT; DEXAMETHASONE; HEMAGGLUTININ; IMMUNOGLOBULIN G1; MEDI 8852; MONOCLONAL ANTIBODY; OSELTAMIVIR; OXYGEN; PLACEBO; SALBUTAMOL; SIALIDASE; UNCLASSIFIED DRUG; MEDI8852;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; BRONCHITIS; CLINICAL ASSESSMENT; COHORT ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HUMAN; IC50; INFLUENZA A; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); LEUKOCYTE COUNT; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES; NONHUMAN; OUTPATIENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SANGER SEQUENCING; SEQUENCE ALIGNMENT; SOUTHERN HEMISPHERE; TREATMENT DURATION; VIRUS GENOME; VIRUS ISOLATION; VIRUS SHEDDING; VISUAL ANALOG SCALE; ADOLESCENT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; INFLUENZA; INFLUENZA A VIRUS; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTININS; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEURAMINIDASE; OSELTAMIVIR; VIRUS SHEDDING; YOUNG ADULT;

EID: 85055605929     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00694-18     Document Type: Article

References (22)

1. Centers for Disease Control and Prevention. 2017. Summary of the 2015-2016 influenza season. US Department of Health and Human Services, Washington, DC. https://www.cdc.gov/flu/about/season/flu-season-2015-2016.htm.
2. De Villiers PJ, Steele AD, Hiemstra LA, Rappaport R, Dunning AJ, Gruber WC, Forrest BD. 2009. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine 28:228–234. https://doi.org/10.1016/j.vaccine.2009.09.092.
3. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM, Centers for Disease Control and Prevention. 2011. Antiviral agents for the treatment and chemo-prophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 60:1–24.
4. Aoki FY, Macleod MD, Paggiaro P, Carewicz O, El Sawy A, Wat C, Griffiths M, Waalberg E, Ward P, IMPACT Study Group. 2003. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 51:123–129. https://doi.org/10.1093/jac/dkg007.
5. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, Rode A, Kinnersley N, Ward P. 2000. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 355:1845–1850. https://doi.org/10.1016/S0140-6736(00)02288-1.
6. Louie JK, Yang S, Acosta M, Yen C, Samuel MC, Schechter R, Guevara H, Uyeki TM. 2012. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 55:1198–1204. https://doi.org/10.1093/cid/cis636.
7. Kallewaard NL, Corti D, Collins PJ, Neu U, McAuliffe JM, Benjamin E, Wachter-Rosati L, Palmer-Hill FJ, Yuan AQ, Walker PA, Vorlaender MK, Bianchi S, Guarino B, De Marco A, Vanzetta F, Agatic G, Foglierini M, Pinna D, Fernandez-Rodriguez B, Fruehwirth A, Silacci C, Ogrodowicz RW, Martin SR, Sallusto F, Suzich JA, Lanzavecchia A, Zhu Q, Gamblin SJ, Skehel JJ. 2016. Structure and function analysis of an antibody recognizing all influenza A subtypes. Cell 166:596–608. https://doi.org/10.1016/j.cell.2016.05.073.
8. Paules CI, Lakdawala S, McAuliffe JM, Paskel M, Vogel L, Kallewaard NL, Zhu Q, Subbarao K. 2017. The hemagglutinin A stem antibody MEDI8852 prevents and controls disease and limits transmission of pandemic influenza viruses. J Infect Dis 216:356–365. https://doi.org/10.1093/infdis/jix292.
9. Mallory RM, Ali SO, Takas T, Kankam M, Dubovsky F, Tseng L. 2017. A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers. Biologicals 50:81– 86. https://doi.org/10.1016/j.biologicals.2017.08.007.
10. Chan-Hui PY, Swiderek KM. 2016. Immunological considerations for developing antibody therapeutics for Influenza A. Hum Vaccin Immu-nother 12:474–477. https://doi.org/10.1080/21645515.2015.1079676.
11. Ramakrishnan B, Viswanathan K, Tharakaraman K, Dancik V, Raman R, Babcock GJ, Shriver Z, Sasisekharan R. 2016. A structural and mathematical modeling analysis of the likelihood of antibody-dependent enhancement in influenza. Trends Microbiol 24:933–943. https://doi.org/10.1016/j.tim.2016.09.003.
12. Gauger PC, Vincent AL, Loving CL, Lager KM, Janke BH, Kehrli ME, Jr, Roth JA. 2011. Enhanced pneumonia and disease in pigs vaccinated with an inactivated human-like (delta-cluster) H1N2 vaccine and challenged with pandemic 2009 H1N1 influenza virus. Vaccine 29:2712–2719. https://doi.org/10.1016/j.vaccine.2011.01.082.
13. Vincent AL, Lager KM, Janke BH, Gramer MR, Richt JA. 2008. Failure of protection and enhanced pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an inactivated classical swine H1N1 vaccine. Vet Microbiol 126:310–323. https://doi.org/10.1016/j.vetmic .2007.07.011.
14. Khurana S, Loving CL, Manischewitz J, King LR, Gauger PC, Henningson J, Vincent AL, Golding H. 2013. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med 5:200ra114. https://doi.org/10.1126/scitranslmed.3006366.
15. McKimm-Breschkin JL, Fry AM. 2016. Meeting report: 4th ISIRV antiviral group conference: novel antiviral therapies for influenza and other respiratory viruses. Antiviral Res 129:21–38. https://doi.org/10.1016/j.antiviral.2016.01.012.
16. Sparrow E, Friede M, Sheikh M, Torvaldsen S. 2017. Therapeutic antibodies for infectious diseases. Bull World Health Organ 95:235–237. https://doi.org/10.2471/BLT.16.178061.
17. Deng R, Lee AP, Maia M, Lim JJ, Burgess T, Horn P, Derby MA, Newton E, Tavel JA, Hanley WD. 2018. Pharmacokinetics of MHAA4549A, an anti-influenza A monoclonal antibody, in healthy subjects challenged with influenza A virus in a phase IIa randomized trial. Clin Pharmacokinet 57:367–377. https://doi.org/10.1007/s40262-017-0564-y.
18. Sloan S, Babcock GJ, Szretter K, Bedard SS, Hay C, Williams J, Hershberger E, Trevejo J. 2016. Evaluation of efficacy and emergence of resistance to VIS410, a human monoclonal antibody, in a human challenge model of infection with a p2009 H1N1 virus, abstr. International Society for Influenza and Other Respiratory Virus Diseases, Options IX for the Control of Influenza, Chicago, IL.
19. Balasingam S, Wilder-Smith A. 2016. Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies. Int J Infect Dis 49:18–29. https://doi.org/10.1016/j.ijid.2016.05.013.
20. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG. 2000. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283:1016–1024.
21. International Council on Harmonisation. 1996. Guideline for good clinical practice, E6(R1). ICH, Geneva, Switzerland. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1 _Guideline.pdf.
22. Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, Bohnen AM, Hirst HM, Keene O, Wightman K, GG167 Influenza Study Group. 1997. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 337: 874–880. https://doi.org/10.1056/NEJM199709253371302.